PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

PTC Therapeutics (NASDAQ: PTCT) has announced the approval of equity compensation packages for 35 new employees on March 24, 2025. The compensation includes 12,000 non-statutory stock options and 28,220 restricted stock units (RSUs).

The stock options were granted at an exercise price of $57.03 per share, matching PTC's closing price on the grant date. These options have a 10-year term and vest over four years, with 25% vesting after the first year and 6.25% quarterly thereafter. The RSUs also follow a four-year vesting schedule, with 25% vesting annually.

These inducement grants, approved by PTC's Compensation Committee, comply with Nasdaq Listing Rule 5635(c)(4) and are part of the new employees' compensation packages.

Positive

• Employee retention strategy through long-term equity incentives
• Structured vesting schedule promotes long-term commitment

Negative

• Potential future dilution of existing shareholders
• Additional share-based compensation expense impact on financial statements

WARREN, N.J., March 28, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on March 24, 2025, the company approved non-statutory stock options to purchase an aggregate of 12,000 shares of its common stock and 28,220 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 35 new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.

The inducement grants were approved by PTC's Compensation Committee on March 24, 2025, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

All stock option awards have an exercise price of $57.03 per share, the closing price of PTC's common stock on March 24, 2025, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs will each vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.

ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, X, and LinkedIn.

For more information please contact:

Investors:
Ellen Cavaleri
+1 (615) 618-8228
ecavaleri@ptcbio.com

Media:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302413763.html

SOURCE PTC Therapeutics, Inc.

FAQ

How many shares were granted in PTC Therapeutics' (PTCT) March 2025 inducement grants?

PTC Therapeutics granted 12,000 stock options and 28,220 RSUs to 35 new employees.

What is the exercise price for PTCT's March 2025 stock option grants?

The stock options have an exercise price of $57.03 per share, based on PTC's closing price on March 24, 2025.

What is the vesting schedule for PTC Therapeutics' March 2025 stock options?

The options vest over 4 years: 25% after year one, then 6.25% quarterly until fully vested.

How do the RSUs vest in PTCT's March 2025 inducement grants?

The RSUs vest over 4 years, with 25% vesting on each annual anniversary of the employee's hire date.